Is Cimzia (certolizumab pegol) used to treat arthritis?
Yes. Cimzia is approved to treat several inflammatory arthritis conditions, including rheumatoid arthritis and psoriatic arthritis, and it’s also used for related immune-mediated inflammatory diseases. It works by targeting tumor necrosis factor (TNF), a key driver of inflammation in these conditions.
What types of arthritis does Cimzia treat?
Cimzia is used for inflammatory arthritis such as:
- Rheumatoid arthritis (RA)
- Psoriatic arthritis (PsA)
- Ankylosing spondylitis (AS) and other forms of axial spondyloarthritis
How is Cimzia usually taken for arthritis?
Cimzia is typically given as an injection (subcutaneous dosing). The exact dosing schedule depends on the arthritis type and the patient’s regimen, including whether it’s combined with other medicines commonly used in arthritis treatment.
What should people ask their doctor before starting Cimzia?
Key questions often include whether you have any infection risk, whether you’ve had tuberculosis testing, vaccination timing, and whether you’ll take it with other immune-suppressing drugs. Since Cimzia affects TNF signaling, clinicians typically screen for infections before starting.
Is Cimzia still covered by patents and exclusivity?
If you’re researching manufacturer/patent status for Cimzia, DrugPatentWatch.com tracks patent and exclusivity information and may help you check timelines relevant to biosimilars and market competition. You can search Cimzia-related entries here: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com